NOVABIO Research Profile

What Is Selank?

Selank is a synthetic peptide research entry commonly discussed in neuropeptide literature. This page identifies the material as Selank, with amino acid count 7; synonyms Tuftsin analogue (TP-7). The Selank identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Exact-product regulatory reviewLast verified 2026-10-06
Catalogue identitySelank
Available specifications5mg, 10mg
Evidence snapshot10 trials · 68 publications
Last verified2026-10-06

What Is Selank?

Selank is a synthetic peptide research entry commonly discussed in neuropeptide literature. This page identifies the material as Selank, with amino acid count 7; synonyms Tuftsin analogue (TP-7). The Selank identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

10ClinicalTrials.gov query records
68PubMed query records
6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Selank is organized around neuropeptide characterization, peptide-signaling literature, signal-response studies, and analytical peptide workflows. For Selank, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / StudyPhaseStatusContextLast registry update
NCT00464269Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresPhase 3CompletedEpilepsy2022-07-21
NCT06151093The Effect of Balance Exercises on Cognitive FunctionNACompletedEEG Brain Oscillations, Balance Exercises2024-06-27
NCT05411185The Study on Effects of Acute Exposure to High Altitude Hypoxia on Cognitive Function in LowlandersNot statedCompletedCognition2024-10-15
NCT05076045Effects of PSAPs on Speech ProcessingNACompletedHearing Loss, Age-Related2024-12-05
NCT00504881Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From EpilepsyPhase 3CompletedEpilepsy2018-04-03
NCT01770990Trial of Telephone-based Psychotherapy for Depression With and Without Adjunctive Supportive MailNACompletedDepression2015-07-14

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Functional Connectomic Approach to Studying Selank and Semax Effects.

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2020 Jan

PMID 32342318
Selected PubMed record

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 Jan 1

PMID 41490200
Selected PubMed record

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.

Bulletin of experimental biology and medicine · 2022 Oct

PMID 36322304
Selected PubMed record

The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress.

Current reviews in clinical and experimental pharmacology · 2021

PMID 32621722
Selected PubMed record

Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.

Frontiers in pharmacology · 2016

PMID 26924987
Selected PubMed record

Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.

Bulletin of experimental biology and medicine · 2019 Sep

PMID 31625062

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend
Selank
Available Specifications
5mg, 10mg
Pack Format
10 Vials
CAS Number
129954-34-3
Molecular Formula
C33H57N11O9
Molecular Weight
751.89 g/mol
Amino Acid Count
7
Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Synonyms
Tuftsin analogue (TP-7)
Physical Form
Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 11765600 · Product form must still be matched to the catalogue and batch record.

Research Tools for Selank

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA
Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Selank Research Summary

Identity

Selank; specifications: 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

The research record for Selank is organized around neuropeptide characterization, peptide-signaling literature, signal-response studies, and analytical peptide workflows. For Selank, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Evidence

10 registry records and 68 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Selank is represented here by the catalogue identity Selank. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Selank is organized around neuropeptide characterization, peptide-signaling literature, signal-response studies, and analytical peptide workflows. For Selank, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 10 ClinicalTrials.gov records and 68 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Selank FAQ

What is Selank?

Selank is a synthetic peptide research entry commonly discussed in neuropeptide literature. This page identifies the material as Selank, with amino acid count 7; synonyms Tuftsin analogue (TP-7). The Selank identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

What research records are indexed for Selank?

The synchronized query returned 10 ClinicalTrials.gov records and 68 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Selank FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources
ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved
2026-10-06T12:08:49Z
Inclusion
Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations
Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by
NOVABIO Research
Reviewed date
2026-10-06
Editorial methodology
How NOVABIO builds Research Profiles
Corrections contact
Contact NOVABIO with the page URL and source record.